Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 Inhibitors - Diabetes Therapy
Source : https://link.springer.com/article/10.1007/s13300-022-01204-4
Heart failure with preserved ejection fraction (HFpEF) is a condition with increasing disease burden. Prevalence of HFpEF is increasing, reflecting an increasingly elderly and comorbid population, as well as reinforcing...
Conclusion/Relevance: The European Society of Cardiology (ESC) recently added SGLT2 inhibitors to their guidelines for treatment of heart failure with reduced ejection fraction (HFrEF) following DAPA-HF and EMPEROR-Reduced trials and we suggest that similar changes be made to guidelines to support the use of SGLT2 inhibitors in the management...
Conclusions: Independently associated with a higher risk of death during hospitalization, although the strength of this association varies according to the underlying admission diagnosis. These data highlight the importance of PH in patients with cardiac critical illness.
Comparison of prognostic impact of anticoagulants in heart failure patients with atrial fibrillation and renal dysfunction: direct oral anticoagulants versus vitamin K antagonists - Heart and Vessels
Source : https://link.springer.com/article/10.1007/s00380-022-02027-w
Although high thromboembolic risk was assumed in elderly patients with heart failure (HF) and atrial fibrillation (AF), inadequate control of prothrombin time/international normalized ratio was often observed in patients using...
Conclusion/Relevance: Compared with VKA therapy, DOAC therapy was associated with lower risk of all-cause mortality in the elderly HF patients with AF and renal dysfunction.
Robustness of outcomes in trials evaluating sodium-glucose co-transporter 2 inhibitors for heart failure - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35029056/
doi: 10.1002/ehf2.13785. Online ahead of print. 1 Department of Medicine, University of Mississippi, Jackson, MS, USA. 2 Division of Cardiology, Duke University Medical Center, Durham, NC, USA. 3 Division of...
Conclusion: Improvement in the composite outcome of first HF hospitalization or cardiovascular death was highly concordant and robust across sodium-glucose co-transporter 2 inhibitor trials. In contrast, secondary endpoints of all-cause and cardiovascular mortality were statistically fragile, underscoring the need to power trials for mortality...
Empagliflozin-A New Chance for Patients with Chronic Heart Failure - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35056104/
The heart failure (HF) epidemic is one of the challenges that has been faced by the healthcare system worldwide for almost 25 years. With an ageing world population and a...
Conclusion/Relevance: In this review we discuss the cardioprotective mechanism of the drug in the context of the benefits of empagliflozin use in patients with chronic cardiac insufficiency. Numerous findings confirm that despite its potential limitations, the use of empagliflozin in HF treatment is advantageous and effective.